Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, on Friday announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The